Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2011. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the vesting of awards under the GlaxoSmithKline Share Value Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification of a specific equity transaction rather than a financial results report.
Material Changes
The material change reported is the vesting of 640 Ordinary shares on February 19, 2011, for a connected person of Dr. M. M. Slaoui, a Person Discharging Managerial Responsibility. This transaction relates to an award made under the 2008 Share Value Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly details the compliance notification required under Disclosure and Transparency Rule 3.1.4R(1)(c).
Key Facts for Investor Verification
- Transaction Date: Vesting occurred on February 19, 2011.
- Individual Involved: Dr. M. M. Slaoui (Person Discharging Managerial Responsibility) and his connected person.
- Volume: 640 Ordinary shares vested.
- Plan Details: Award originated from the 2008 GlaxoSmithKline Share Value Plan.
- Notification Date: The Company and the connected person were advised of the transaction on February 21, 2011.